Therapeutic potential of the anti-angiogenesis drug TNP-470.
Neovessel formation is a pre-requisite for tumour growth and dissemination. Inhibition of angiogenesis is a promising approach for the treatment of neoplasms. In recent years, antiangiogenic drugs, such as TNP-470, have entered clinical trials. In this paper, we review the key experimental and clinical data on the role of TNP-470 in anti-tumour treatment.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D003510:Cyclohexanes; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D012717:Sesquiterpenes / Q000627:therapeutic use*